Advertisement

Late recurrence in birdshot chorioretinopathy

Published:September 14, 2021DOI:https://doi.org/10.1016/j.jcjo.2021.08.006

      Abstract

      Objective

      To compare the demographic, clinical, ancillary testing, and multimodal imaging characteristics of birdshot chorioretinopathy (BSCR) patients with late recurrence and birdshot patients with durable remission.

      Patients and Methods

      This was a retrospective observational case series. The above-mentioned parameters were studied in BSCR patients with late recurrence (group 1) and BSCR patients with durable remission (group 2).

      Results

      Fifty-five patients were included in this study. The average age of patients was 62.1 ± 11.1 years (range, 35–88 years). Groups 1 and 2 included 20 (36.4%) and 35 (63.6%) patients, respectively. In group 1, the average age of patients was 60.5 ± 10.39 years (range, 35–79 years). The female-to-male ratio was 16:4. In group 2, the average age of patients was 63.1 ± 11.6 years (range, 37–88 years). The female-to-male ratio was 22:13. None of the demographic, clinical, ancillary testing, and multimodal imaging parameters were statistically significantly different between the two groups. Using a receiver operating characteristics (ROC) curve, we found that the ideal duration of successful therapy to induce durable remission was 30 months with 70% sensitivity and 40% specificity (ideal point on the curve). A Kaplan–Meier survival curve demonstrated that late recurrence was seen within 30 months after stopping successful treatment of patients with BSCR.

      Conclusion

      There are no demographic, clinical, ancillary testing, or multimodal imaging characteristics that can predict late recurrence in BSCR patients. However, we found that 30 months of successful treatment may be ideal and recommended.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Murray PI
        • Duker JS
        • Keane PA
        • Denniston AK.
        Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment.
        Orphanet J Rare Dis. 2016; 11: 61
        • Keane PA
        • Allie M
        • Turner SJ
        • et al.
        Characterization of birdshot chorioretinopathy using extramacular enhanced depth optical coherence tomography.
        JAMA Ophthalmol. 2013; 131: 341-350
        • Molins B
        • Mesquida M
        • Llorenç V
        • Sainz de la Maza M
        • Adán A.
        Elevated serum immune mediators and subclinical inflammation in HLA-A29-associated birdshot chorioretinopathy.
        Ocul Immunol Inflamm. 2016; 24: 647-652
        • Gasch AT
        • Smith JA
        • retinochoroidopathy Whitcup SM.Birdshot
        Br J Ophthalmol. 1999; 83: 241-249
        • Radwan AE
        • Parikh R
        • Baheti U
        • Austin M
        • Foster CS.
        Risk factors associated with relapse of birdshot retinochoriodopathy.
        Invest Ophthalmol Vis Sci. 2012; 53: 2793
        • Levinson RD
        • Brezin A
        • Rothova A
        • Accorinti M
        • Holland GN.
        Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference.
        Am J Ophthalmol. 2006; 141: 185-187
        • Maleki A
        • Swan RT
        • Silpa-Archa S
        • Preble JM
        • He Y
        • Foster CS.
        Short-wavelength automated perimetry parameters at baseline and following remission in patients with birdshot retinochoroidopathy.
        Am J Ophthalmol. 2016; 163 (e6): 83-92
        • Thorne JE
        • Jabs DA
        • Peters GB
        • Hair D
        • Dunn JP
        • Kempen JH.
        Birdshot retinochoroidopathy: ocular complications and visual impairment.
        Am J Ophthalmol. 2005; 140: 45-51
        • Rothova A
        • Berendschot TT
        • Probst K
        • van Kooij B
        • Baarsma GS.
        Birdshot chorioretinopathy: long-term manifestations and visual prognosis.
        Ophthalmology. 2004; 111: 954-959
        • Becker MD
        • Wertheim MS
        • Smith JR
        • Rosenbaum JT.
        Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression.
        Ocul Immunol Inflamm. 2005; 13: 289-293
        • retinopathy Vitale AT.Birdshot
        J Ophthalmic Vis Res. 2014; 9: 350-361
        • Tomkins-Netzer O
        • Taylor SR
        • Lightman S.
        Long-term clinical and anatomic outcome of birdshot chorioretinopathy.
        JAMA Ophthalmol. 2014; 132: 57-62
        • Crowell EL
        • France R
        • Majmudar P
        • Jabs DA
        • Thorne JE.
        Birdshot chorioretinitis: treatment and remission outcomes.
        Invest Ophthalmol Vis Sci. 2019; 60: 3506
        • Birch DG
        • Williams PD
        • Callanan D
        • Wang R
        • Locke KG
        • Hood DC.
        Macular atrophy in birdshot retinochoroidopathy: an optical coherence tomography and multifocal electroretinography analysis.
        Retina. 2010; 30: 930-937
        • Lages V
        • Skvortsova N
        • Jeannin B
        • Gasc A
        • Herbort CP.
        Low-grade “benign” birdshot retinochoroiditis: prevalence and characteristics.
        Int Ophthalmol. 2019; 39: 2111-2120